Allogeneic murine mesenchymal stem cells: Migration to inflamed joints in vivo and amelioration of collagen induced arthritis when transduced to express CTLA4Ig

Stem Cells and Development

Volumn 22, Issue 24, 2013, Pages 3203-3213

  Sullivan, Catherine ^a   Barry, Frank ^a   Ritter, Thomas ^a   O'Flatharta, Cathal ^a   Howard, Linda ^a   Shaw, Georgina ^a   Anegon, Ignacio ^b   Murphy, Mary ^a  

^a NATIONAL UNIVERSITY OF IRELAND   (Ireland)

^b CNRS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ADENOVIRUS VECTOR; BONE MORPHOGENETIC PROTEIN 2; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 4; TUMOR NECROSIS FACTOR ALPHA;

ADIPOGENESIS; ALLOGENEIC MESENCHYMAL STEM CELLS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTHRITIS; ARTICLE; BONE DEVELOPMENT; CELL DIFFERENTIATION; CELL HOMING; CELL MIGRATION; CELL POPULATION; CELL STIMULATION; CELL SURFACE; CHONDROGENESIS; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DNA ISOLATION; FLOW CYTOMETRY; IN VITRO STUDY; IN VIVO STUDY; MALE; MESENCHYMAL STEM CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; T LYMPHOCYTE; TH1 TH2 BALANCE; VIRAL GENE DELIVERY SYSTEM;

ALLOGRAFTS; ANIMALS; ARTHRITIS, EXPERIMENTAL; COLLAGEN; GENETIC THERAPY; IMMUNOCONJUGATES; JOINTS; MESENCHYMAL STROMAL CELLS; MICE; T-LYMPHOCYTES, CYTOTOXIC; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84889675249     PISSN: 15473287     EISSN: 15578534     Source Type: Journal    
DOI: 10.1089/scd.2013.0248     Document Type: Article

References (54)

1. Choy EH and GS Panayi. (2001). Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 344:907-916
2. Firestein GS. (2003). Evolving concepts of rheumatoid arthritis. Nature 423:356-361
3. Furst DE. (2010). Development of TNF inhibitor therapies for the treatment of rheumatoid arthritis. Clin Exp Rheumatol 28(3 Suppl 59):S5-S12
4. Finckh A, A Ciurea, L Brulhart, D Kyburz, B Moller, S Dehler, S Revaz, J Dudler and C Gabay. (2007). B cell depletion may be more effective than switching to an alternative anti-Tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti-Tumor necrosis factor agents. Arthritis Rheum 56:1417-1423
5. Genovese MC, JD McKay, EL Nasonov, EF Mysler, NA da Silva, E Alecock, T Woodworth and JJ Gomez-Reino. (2008). Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: The tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis Rheum 58:2968-2980
6. Guyot P, P Taylor, R Christensen, L Pericleous, C Poncet, M Lebmeier, P Drost and G Bergman. (2011). Abatacept with methotrexate versus other biologic agents in treatment of patients with active rheumatoid arthritis despite methotrexate: A network meta-Analysis. Arthritis Res Ther 13:R204
7. Barry FP and JM Murphy. (2004). Mesenchymal stem cells: Clinical applications and biological characterization. Int J Biochem Cell Biol 36:568-584
8. Duffy MM, J Pindjakova, SA Hanley, C McCarthy, GA Weidhofer, EM Sweeney, K English, G Shaw, JM Murphy, et al. (2011). Mesenchymal stem cell inhibition of T-helper 17 cell-differentiation is triggered by cell-cell contact and mediated by prostaglandin E2 via the EP4 receptor. Eur J Immunol 41:2840-2851
9. Le Blanc K, I Rasmusson, C Gotherstrom, C Seidel, B Sundberg, M Sundin, K Rosendahl, C Tammik and O Ringden. (2004). Mesenchymal stem cells inhibit the expression of CD25 (interleukin-2 receptor) and CD38 on phytohaemagglutinin- Activated lymphocytes. Scand J Immunol 60:307-315
10. Potian JA, H Aviv, NM Ponzio, JS Harrison and P Rameshwar. (2003). Veto-like activity of mesenchymal stem cells: Functional discrimination between cellular responses to alloantigens and recall antigens. J Immunol 171:3426-3434
11. Majumdar MK, M Keane-Moore, D Buyaner, WB Hardy, MA Moorman, KR McIntosh and JD Mosca. (2003). Characterization and functionality of cell surface molecules on human mesenchymal stem cells. J Biomed Sci 10:228-241
12. Alm JJ, HM Koivu, TJ Heino, TA Hentunen, S Laitinen and HT Aro. (2010). Circulating plastic adherent mesenchymal stem cells in aged hip fracture patients. J Orthop Res 28:1634-1642
13. Loebinger MR, PG Kyrtatos, M Turmaine, AN Price, Q Pankhurst, MF Lythgoe and SM Janes. (2009). Magnetic resonance imaging of mesenchymal stem cells homing to pulmonary metastases using biocompatible magnetic nanoparticles. Cancer Res 69:8862-8867
14. Augello A, R Tasso, SM Negrini, R Cancedda and G Pennesi. (2007). Cell therapy using allogeneic bone marrow mesenchymal stem cells prevents tissue damage in collagen-induced arthritis. Arthritis Rheum 56:1175-1186
15. Gonzá lez MA, E Gonzalez-Rey, L Rico, D Büscher and M Delgado. (2009). Treatment of experimental arthritis by inducing immune tolerance with human adiposederived mesenchymal stem cells. Arthritis Rheum 60:1006-1019
16. Mao F, WR Xu, H Qian, W Zhu, YM Yan, QX Shao and HX Xu. (2010). Immunosuppressive effects of mesenchymal stem cells in collagen-induced mouse arthritis. Inflamm Res 59:219-225
17. Liu Y, R Mu, S Wang, L Long, X Liu, R Li, J Sun, J Guo, X Zhang, et al. (2010). Therapeutic potential of human umbilical cord mesenchymal stem cells in the treatment of rheumatoid arthritis. Arthritis Res Ther 12:R210
18. Sullivan C, JM Murphy, MD Griffin, RM Porter, CH Evans, C O'Flatharta, G Shaw and F Barry. (2012). Genetic mismatch affects the immunosuppressive properties of mesenchymal stem cells in vitro and their ability to influence the course of collagen-induced arthritis. Arthritis Res Ther 14:R167
19. Djouad F, V Fritz, F Apparailly, P Louis-Plence, C Bony, J Sany, C Jorgensen and D Noel. (2005). Reversal of the immunosuppressive properties of mesenchymal stem cells by tumor necrosis factor alpha in collagen-induced arthritis. Arthritis Rheum 52:1595-1603
20. Schurgers E, H Kelchtermans, T Mitera, L Geboes and P Matthys. (2010). Discrepancy between the in vitro and in vivo effects of murine mesenchymal stem cells on T-cell proliferation and collagen-induced arthritis. Arthritis Res Ther 12:R31
21. Chen B, J Hu, L Liao, Z Sun, Q Han, Z Song and RC Zhao. (2010). Flk-1 + mesenchymal stem cells aggravate collageninduced arthritis by up-regulating interleukin-6. Clin Exp Immunol 159:292-302
22. Choi JJ, SA Yoo, SJ Park, YJ Kang, WU Kim, IH Oh and CS Cho. (2008). Mesenchymal stem cells overexpressing inter-leukin-10 attenuate collagen-induced arthritis in mice. Clin Exp Immunol 153:269-276
23. Papadopoulou A, M Yiangou, E Athanasiou, N Zogas, P Kaloyannidis, I Batsis, A Fassas, A Anagnostopoulos and E Yannaki. (2012). Mesenchymal stem cells are conditionally therapeutic in preclinical models of rheumatoid arthritis. Ann Rheum Dis 71:1733-1740
24. Park MJ, HS Park, ML Cho, HJ Oh, YG Cho, SY Min, BH Chung, JW Lee, HY Kim and SG Cho. (2011). Transforming growth factor beta-Transduced mesenchymal stem cells ameliorate experimental autoimmune arthritis through reciprocal regulation of Treg/Th17 cells and osteoclastogenesis. Arthritis Rheum 63:1668-1680
25. Sharpe AH and AK Abbas. (2006). T-cell costimulation-biology, therapeutic potential, and challenges. N Engl J Med 355:973-975
26. Tse WT, JD Pendleton, WM Beyer, MC Egalka and EC Guinan. (2003). Suppression of allogeneic T-cell proliferation by human marrow stromal cells: Implications in transplantation. Transplantation 75:389-397
27. Zappia E, S Casazza, E Pedemonte, F Benvenuto, I Bonanni, E Gerdoni, D Giunti, A Ceravolo, F Cazzanti, et al. (2005). Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy. Blood 106:1755-1761
28. Aggarwal S and MF Pittenger. (2005). Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 105:1815-1822
29. English K, FP Barry and BP Mahon. (2008). Murine mesenchymal stem cells suppress dendritic cell migration, maturation and antigen presentation. Immunol Lett 115:50-58
30. Hu W, J Wang, X He, H Zhang, F Yu, L Jiang, D Chen, J Chen and J Dou. (2011). Human umbilical blood mononuclear cell-derived mesenchymal stem cells serve as interleukin-21 gene delivery vehicles for epithelial ovarian cancer therapy in nude mice. Biotechnol Appl Biochem 58:397-404
31. Fei S, X Qi, S Kedong, J Guangchun, L Jian and Q Wei. (2012). The antitumor effect of mesenchymal stem cells transduced with a lentiviral vector expressing cytosine deaminase in a rat glioma model. J Cancer Res Clin Oncol 138:347-357
32. Cihova M, V Altanerova and C Altaner. (2011). Stem cell based cancer gene therapy. Mol Pharm 8:1480-1487
33. Deng Y, X Guo and Q Yuan. (2003). Efficiency of adenoviral vector mediated CTLA4Ig gene delivery into mesenchymal stem cells. Chin Med J (Engl) 116:1649-1654
34. Choi EW, IS Shin, HW Lee, SY Park, JH Park, MH Nam, JS Kim, SK Woo, EJ Yoon, et al. (2011). Transplantation of CTLA4Ig gene-Transduced adipose tissue-derived mesenchymal stem cells reduces inflammatory immune response and improves Th1/Th2 balance in experimental autoimmune thyroiditis. J Gene Med 13:3-16
35. Zhang X, C Zhang, T Tang, Z Qu, J Lou and K Dai. (2008). Immunomodulatory and osteogenic differentiation effects of mesenchymal stem cells by adenovirus-mediated coexpression of CTLA4Ig and BMP2. J Orthop Res 26:314-321
36. Treacy O, AE Ryan, T Heinzl, L O'Flynn, M Cregg, M Wilk, F Odoardi, P Lohan, T O'Brien, M Nosov and T Ritter. (2012). Adenoviral transduction of mesenchymal stem cells: In vitro responses and in vivo immune responses after cell transplantation. PLoS One 7:e42662
37. Gong N, U Pleyer, J Yang, K Vogt, M Hill, I Anegon, HD Volk and T Ritter. (2006). Influence of local and systemic CTLA4Ig gene transfer on corneal allograft survival. J Gene Med 8:459-467
38. McMahon JM, S Conroy, M Lyons, U Greiser, C O'Shea, P Strappe, L Howard, M Murphy, F Barry and T O'Brien. (2006). Gene transfer into rat mesenchymal stem cells: A comparative study of viral and nonviral vectors. Stem Cells Dev 15:87-96
39. Murphy JM, DJ Fink, EB Hunziker and FP Barry. (2006). Stem cell therapy in a caprine model of osteoarthritis. Arthritis Rheum 48:3464-3474
40. Eljaafari A, ML Tartelin, H Aissaoui, G Chevrel, B Osta, F Lavocat and P Miossec. (2012). Bone marrow-derived and synovium-derived mesenchymal cells promote Th17 cell expansion and activation through caspase 1 activation: Contribution to the chronicity of rheumatoid arthritis. Arthritis Rheum 64:2147-2157
41. Marinova-Mutafchieva L, RO Williams, K Funa, RN Maini and NJ Zvaifler. (2002). Inflammation is preceded by tumor necrosis factor-dependent infiltration of mesenchymal cells in experimental arthritis. Arthritis Rheum 46:507-513
42. Kawada H, J Fujita, K Kinjo, Y Matsuzaki, M Tsuma, H Miyatake, Y Muguruma, K Tsuboi, Y Itabashi, et al. (2004). Nonhematopoietic mesenchymal stem cells can be mobilized and differentiate into cardiomyocytes after myocardial infarction. Blood 104:3581-3587
43. Li X and SS Makarov. (2006). An essential role of NF-kappaB in the ''tumor-like'' phenotype of arthritic synoviocytes. Proc Natl Acad Sci U S A 103:17432-17437
44. Karp JM and GS Leng Teo. (2009). Mesenchymal stem cell homing: The devil is in the details. Cell Stem Cell 4:206-216
45. Quante M, SP Tu, H Tomita, T Gonda, SS Wang, S Takashi, GH Baik, W Shibata, B Diprete, et al. (2011). Bone marrowderived myofibroblasts contribute to the mesenchymal stem cell niche and promote tumor growth. Cancer Cell 19:257-272
46. Wang CH, WJ Cherng, NI Yang, LT Kuo, CM Hsu, HI Yeh, YJ Lan, CH Yeh and WL Stanford. (2008). Late-outgrowth endothelial cells attenuate intimal hyperplasia contributed by mesenchymal stem cells after vascular injury. Arterioscler Thromb Vasc Biol 28:54-60
47. Teo GS, JA Ankrum, R Martinelli, SE Boetto, K Simms, TE Sciuto, AM Dvorak, JM Karp and CV Carman. (2012). Mesenchymal stem cells transmigrate between and directly through tumor necrosis factor-A-Activated endothelial cells via both leukocyte-like and novel mechanisms. Stem Cells 30:2472-2486
48. Lee RH, MJ Seo, AA Pulin, CA Gregory, J Ylostalo and DJ Prockop. (2009). The CD34-like protein PODXL and alpha6-integrin (CD49f) identify early progenitor MSCs with increased clonogenicity and migration to infarcted heart in mice. Blood 113:816-826
49. Zhao W, JJ Li, DY Cao, X Li, LY Zhang, Y He, SQ Yue, DS Wang and KF Dou. (2012). Intravenous injection of mesenchymal stem cells is effective in treating liver fibrosis. World J Gastroenterol 18:1048-1058
50. Baertschiger RM, V Serre-Beinier, P Morel, D Bosco, M Peyrou, S Cle'ment, A Sgroi, A Kaelin, LH Buhler and C Gonelle-Gispert. (2009). Fibrogenic potential of human multipotent mesenchymal stromal cells in injured liver. PLoS One 4:e6657
51. Streetz KL, T Wüstefeld, C Klein, MP Manns and C Trautwein. (2001). Mediators of inflammation and acute phase response in the liver. Cell Mol Biol (Noisy-le-grand) 47:661-673
52. Peister A, JA Mellad, BL Larson, BM Hall, LF Gibson and DJ Prockop. (2004). Adult stem cells from bone marrow (MSCs) isolated from different strains of inbred mice vary in surface epitopes, rates of proliferation, and differentiation potential. Blood 103:1662-1668
53. Billiau A and P Matthys. (2011). Collagen-induced arthritis and related animal models: How much of their pathogenesis is auto-immune, how much is auto-inflammatory? Cytokine Growth Factor Rev 22:339-344
54. Marti L, R Golmia, AP Golmia, AT Paes, DD Guilhen, CA Moreira-Filho and M Scheinberg. (2009). Alterations in cytokine profile and dendritic cells subsets in peripheral blood of rheumatoid arthritis patients before and after biologic therapy. Ann N Y Acad Sci 1173:334-342